29 January 2020 - The global Cardiac
Biomarkers Market size was
estimated at USD 4.7 billion in 2015. Rising prevalence of cardiovascular
diseases globally and escalating popularity of POC testing are some of the main
factors contributing toward the market growth.
Cardiac
biomarkers are the substances released in the bloodstream due to heart related
damage and stress. as a result of insufficient blood supply to the heart. The
detection of the biomarkers is used for the identification of various heart
conditions such as, acute coronary syndrome, acute myocardial infarction,
ischemia, congestive heart failure.
High
prevalence of cardiovascular diseases worldwide has resulted into a significant
growth in the cardiac biomarkers market. According to the WHO, about 17.5
million people globally suffer from some heart condition. The increasing preference
to the use of the cardiac kits and more awareness among the people regarding
the application of the cardiac biomarkers is expected to augment the market in
the near future.
Type Insights
Based
on the types, the cardiac biomarker market is classified into the troponin,
creatinine- kinase MB, Natriuretic peptides- b-type Natriuretic peptide and N
terminal pro b–type Natriuretic peptide, myoglobin, and others. Troponin tests
are in large demand for the detection of the AMI with efficient diagnosis of
cardiovascular disorders. This growing demand has resulted in tremendous market
growth of this segment.
Natriuretic
peptides held the second largest share in 2015. The increasing incidence of the
cardiovascular disorders has led to the surge in demand of these products,
further attributing to the growth of the segment.
Application Insights
Based
on application, the market is segmented into ACS (acute coronary syndrome), AMI
(acute myocardial infarction), and CHF (congestive heart failure). The cardiac
biomarkers have major application in the diagnosis of ACS and thus, this
segment accounted for largest revenue generating sector. According to American
Heart Association (AHA), the Americans are estimated to spend around USD 150
billion for treating ACS posing a huge social and economic burden.
Followed
by ACS, myocardial infarction held the second largest market share in 2015. The
increasing number of the geriatric population has led to the growth of the
sector, in this segment, as the elderly population is more prone to
cardiac-related ailments. In addition, the growing unhealthy, sedentary
lifestyle and alcohol consumption has further augmented the chances of the
heart problems, hence, boosting the cardiac biomarker market growth.
End User Insights
The
end user segment is fragmented into two types namely, laboratory testing and
point of testing (PoC). The laboratory testing held the largest revenue share
in 2015. Increasing incidence and prevalence of heart-related diseases is
expected to flourish the segment growth.
The
PoC testing segment is projected to witness growth at the highest CAGR during
the forecast period. The rising demand for the PoC segment has led to the
growth of the segment. Moreover, the rising awareness in the developing
countries regarding the use of PoC testing and its application in cardiac
biomarkers has nurtured the market growth.
Regional Insights
The
regional market considered in the cardiac biomarkers sector are North America,
Europe, Asia Pacific, Latin America, and MEA. North America is estimated to
account for the largest revenue share in 2015. The high prevalence of the
cardiac disorders in the North America has boosted the application of cardiac
biomarkers in North America. Moreover, the increasing popularity of the PoC
testing has added to the growth of the market.
The
Asia Pacific region is anticipated to witness fastest growth owing to large
population base with target disease. The high prevalence of the cardiovascular
diseases has augmented the cardiac biomarker products in the Asia Pacific
region. The major emerging markets such as India and China attributes for the
major growth in the cardiac biomarker segment in the Asia Pacific region.
Competitive Insights
The
major players in the cardiac biomarker market include Roche Diagnostics;
Siemens Healthcare; Alere, Inc.; Beckman Coulter, Inc.; Thermo Fisher
Scientific, Inc.; Bio-Rad Laboratories, Inc.; Becton, Dickinson and Company;
bioMérieux SA; and Randox Laboratories Ltd.
The
new product launches and increasing development in the products are major
growth trends in the cardiac biomarker market. The rising demand for efficient
and rapid diagnostics of cardiovascular diseases is the key contributing factor
to the sector growth. Alere triage panel, manufactured by Alere, Inc., is a
combination of three major biomarkers namely, CK-MB, myoglobin, and troponin I.
The test is handy due to efficient detection of the cardiovascular disease and,
being a combination product, there is a great demand for the test in the
market.
Market Segment:
Cardiac Biomarkers Type Outlook
(Revenue, USD Million, 2013 - 2024)
• Troponin
• CK-MB
• Natriuretic peptides - BNP and
NT-proBNP
• Myoglobin
• Others
Cardiac Biomarkers Market Application
Outlook (Revenue, USD Million, 2013 - 2024)
• Acute Coronary Syndrome
• Myocardial infarction
•
Congestive heart failure
• Others
Cardiac Biomarkers Market End-use
Outlook (Revenue, USD Million, 2013 - 2024)
• Laboratory Testing
• Point of Care Testing
Cardiac Biomarkers Regional Outlook
(Revenue, USD Million, 2013 - 2024)
• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• Asia Pacific
• China
• India
• Latin America
• Brazil
• Mexico
• MEA
• South Africa
• Middle East
Comments
Post a Comment